丙肝吧 关注:46,108贴子:1,201,055

新药大趋势了,贴吧各种新药治疗贴汇总。

只看楼主收藏回复

施贵宝帖子有了,欧盟组合有了,吉利德二代有了,吉利德一代在新药贴吧,第一代蛋白酶抑制剂有了,到今天 所有新药帖子全了。
1、harvoni (吉二代):
http://tieba.baidu.com/p/3425081669?share=9105&fr=share
2、欧盟组合(sof加dav)
http://tieba.baidu.com/p/3330910115?share=9105&fr=share
3、第一代蛋白酶抑制剂(干扰素三联):
http://tieba.baidu.com/p/3217605719?share=9105&fr=share
4、吉利德一代sovaldi:
http://tieba.baidu.com/p/3148173762?share=9105&fr=share
5、施贵宝dav加asv:
http://tieba.baidu.com/p/3012231186?share=9105&fr=share


IP属地:北京来自Android客户端1楼2014-11-22 21:46回复


    IP属地:北京来自Android客户端2楼2014-11-22 21:46
    收起回复
      6、sovaldi加oly(吉利德,强生组合):
      1b治愈率93%,但价格毫无优势,注定昙花一现
      http://tieba.baidu.com/p/3251696754?share=9105&fr=share


      IP属地:北京来自Android客户端7楼2014-11-22 22:11
      收起回复
        好帖


        来自手机贴吧8楼2014-11-22 22:28
        收起回复
          好贴,让大家对新药有全面了解,赞


          来自手机贴吧9楼2014-11-22 22:42
          收起回复
            哇 新药专家了!


            来自iPhone客户端10楼2014-11-23 00:57
            回复
              顶....新药越多价格降得越快


              IP属地:贵州来自iPhone客户端12楼2014-11-23 17:54
              收起回复
                感谢楼主分享。
                我母亲2a型,用不了干扰素,现在纯口服药只能用吉1和吉2。
                能说下你了解的目前吉1,2购药渠道和价格么?真心感谢!


                16楼2014-11-24 21:52
                收起回复
                  daclatasvir 这是什么药?


                  17楼2014-11-24 22:37
                  收起回复
                    顶个


                    IP属地:湖北来自Android客户端21楼2014-11-25 23:21
                    收起回复
                      Among those with genotype 1, 83 percent of the participants who took 25 mg of GS-5816 plus ribavirin achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure), compared with 81 percent of those who took 100 mg with ribavirin. In the arms that did not receive ribavirin, 87 percent of those who took 25 mg of GS-5816 were cured, compared with 90 percent of those who took 100 mg.
                      Among those with genotype 2 who did not take ribavirin, a respective 77 percent and 88 percent of the low and high doses of GS-5816 were cured. As for the genotype 2s who did take ribavirin, 88 percent of both those on the high and the low dose of GS-5816 achieved an SVR12.
                      Among those with genotype 3 who did not take ribavirin, a respective 100 percent and 96 percent of those in the low- and high-dose arms were cured. (One person in the high-dose arm withdrew consent to be in the study, which is why that cure rate wasn’t 100 percent.) As for the genotype 3s who did tak


                      IP属地:北京来自Android客户端26楼2014-11-29 19:40
                      回复


                        IP属地:北京来自Android客户端27楼2014-11-29 19:46
                        收起回复
                          巴基斯坦批准sovaldi。 11月24


                          IP属地:北京来自Android客户端28楼2014-11-29 20:00
                          收起回复
                            这两天没啥好消息


                            IP属地:北京来自Android客户端29楼2014-12-02 22:21
                            收起回复


                              IP属地:北京来自Android客户端30楼2014-12-05 20:11
                              收起回复